

Menaka Pai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5293105/publications.pdf>

Version: 2024-02-01

64
papers

2,869
citations

279487

23
h-index

174990

52
g-index

67
all docs

67
docs citations

67
times ranked

3959
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 149-156.	1.9	76
2	Vaccine-induced immune thrombotic thrombocytopenia. <i>Lancet Haematology</i> , 2022, 9, e73-e80.	2.2	114
3	The Epidemiology of Thrombosis With Thrombocytopenia Syndrome: Analogies With Heparin-Induced Thrombocytopenia. <i>Annals of Internal Medicine</i> , 2022, 175, 604-605.	2.0	6
4	Vaccine-induced immune thrombotic thrombocytopenia (VITT) – update on diagnosis and management considering different resources: Response to Comment from Yamada et al. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 542-543.	1.9	8
5	Epidemiology of VITT. <i>Seminars in Hematology</i> , 2022, 59, 72-75.	1.8	30
6	American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. <i>Blood Advances</i> , 2021, 5, 872-888.	2.5	310
7	Heparin-induced thrombocytopenia. <i>Cmaj</i> , 2021, 193, E736-E736.	0.9	29
8	Managing drug shortages during a pandemic: tocilizumab and COVID-19. <i>Cmaj</i> , 2021, 193, E771-E776.	0.9	12
9	Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2082-2088.	1.9	14
10	Vaccine-induced immune thrombotic thrombocytopenia presenting with normal platelet count. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12596.	1.0	12
11	Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1677-1680.	1.8	22
12	Acquired Hemophilia A. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1131-1142.	0.9	11
13	Editorial on Thaler et al. long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. <i>Thromb Res 2021 in press. Thrombosis Research</i> , 2021, 207, 158-160.	0.8	1
14	Perioperative Anemia Management in Women Undergoing Gynecologic Procedures: A 10 Year Multisite Study. <i>Blood</i> , 2021, 138, 752-752.	0.6	0
15	Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study. <i>BMJ Open</i> , 2021, 11, e052019.	0.8	7
16	Letter to the editor. <i>American Journal of Emergency Medicine</i> , 2020, 38, 153-154.	0.7	2
17	ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2496-2502.	1.9	188
18	ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2486-2495.	1.9	142

#	ARTICLE	IF	CITATIONS
19	Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2503-2512.	1.9	25
20	A user guide to the American Society of Hematology clinical practice guidelines. <i>Blood Advances</i> , 2020, 4, 2095-2110.	2.5	14
21	A regional massive hemorrhage protocol developed through a modified Delphi technique. <i>CMAJ Open</i> , 2019, 7, E546-E561.	1.1	17
22	Strategies for eliciting and synthesizing evidence for guidelines in rare diseases. <i>BMC Medical Research Methodology</i> , 2019, 19, 67.	1.4	38
23	A Regional Massive Hemorrhage Protocol: Designed with a Modified Delphi Technique to Obtain Consensus. <i>Blood</i> , 2019, 134, 5792-5792.	0.6	0
24	Oral anticoagulant dosing, administration, and storage: a cross-sectional survey of Canadian health care providers. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 180-185.	1.0	8
25	The value of clinical practice guidelines in hematology. <i>Blood Advances</i> , 2018, 2, 3196-3197.	2.5	0
26	Laboratory Evaluation of Hemostatic and Thrombotic Disorders. , 2018, , 1922-1931.		0
27	Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial. <i>PLoS ONE</i> , 2018, 13, e0198285.	1.1	11
28	Thromboprophylaxis after Knee Arthroscopy. <i>New England Journal of Medicine</i> , 2017, 376, 580-583.	13.9	7
29	Direct Oral Anticoagulants in the Real World. <i>Canadian Journal of Nursing Research</i> , 2017, 49, 105-107.	0.6	5
30	Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. <i>Blood</i> , 2017, 130, 1104-1113.	0.6	152
31	Direct Oral Anticoagulants in the Real World: Insights into Canadian Health Care Providers's™ Understanding of Medication Dosing and Use. <i>Canadian Journal of General Internal Medicine</i> , 2017, 12, .	0.6	2
32	Survival after ultramassive transfusion: a review of 1360 cases. <i>Transfusion</i> , 2016, 56, 558-563.	0.8	60
33	Exposure to <sc>ABO</sc> â€œnonidentical blood associated with increased inâ€œhospital mortality in patients with group <sc>A</sc> blood. <i>Transfusion</i> , 2016, 56, 550-557.	0.8	18
34	Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. <i>Blood</i> , 2016, 127, 400-410.	0.6	94
35	A benchmarking program to reduce red blood cell outdating: implementation, evaluation, and a conceptual framework. <i>Transfusion</i> , 2015, 55, 1621-1627.	0.8	5
36	Failure of Anticoagulant Thromboprophylaxis. <i>Critical Care Medicine</i> , 2015, 43, 401-410.	0.4	106

#	ARTICLE	IF	CITATIONS
37	Rivaroxaban for Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia Study. <i>Blood</i> , 2015, 126, 3468-3468.	0.6	4
38	Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1120-1128.	1.8	17
39	Design of the rivaroxaban for heparin-induced thrombocytopenia study. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 485-492.	1.0	29
40	Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1254-1259.	1.9	26
41	Utilization of Universal Group O Blood By Non Group O Recipients. <i>Blood</i> , 2014, 124, 5103-5103.	0.6	1
42	How I manage heavy menstrual bleeding. <i>British Journal of Haematology</i> , 2013, 162, 721-729.	1.2	16
43	Strategies to enhance venous thromboprophylaxis in hospitalized medical patients (SENTRY): a pilot cluster randomized trial. <i>Implementation Science</i> , 2013, 8, 1.	2.5	356
44	Neutralization of Heparin Activity. <i>Handbook of Experimental Pharmacology</i> , 2012, , 265-277.	0.9	31
45	Intraoperative anticoagulation and limb amputations in patients with immune heparin-induced thrombocytopenia who require vascular surgery. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 148-150.	1.9	15
46	Barriers and potential solutions toward optimal prophylaxis against deep vein thrombosis for hospitalized medical patients: A survey of healthcare professionals. <i>Journal of Hospital Medicine</i> , 2012, 7, 28-34.	0.7	25
47	Statins in the prevention of venous thromboembolism: A meta-analysis of observational studies. <i>Thrombosis Research</i> , 2011, 128, 422-430.	0.8	49
48	Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin release assay: a 30-month, 16-patient case series. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2389-2396.	1.9	127
49	Critical Values in the Coagulation Laboratory. <i>American Journal of Clinical Pathology</i> , 2011, 136, 836-841.	0.4	24
50	A prospective cohort study of light transmission platelet aggregometry for bleeding disorders: Is testing native platelet-rich plasma non-inferior to testing platelet count adjusted samples?. <i>Thrombosis and Haemostasis</i> , 2011, 106, 675-682.	1.8	39
51	Diagnostic Usefulness of a Lumi-Aggregometer Adenosine Triphosphate Release Assay for the Assessment of Platelet Function Disorders. <i>American Journal of Clinical Pathology</i> , 2011, 136, 350-358.	0.4	70
52	Preventing venous thromboembolism in long-term care residents: Cautious advice based on limited data. <i>Cleveland Clinic Journal of Medicine</i> , 2010, 77, 123-130.	0.6	9
53	Diagnostic Assessment of Platelet Disorders: What Are the Challenges to Standardization?. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 131-138.	1.5	40
54	Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 676-684.	1.9	141

#	ARTICLE	IF	CITATIONS
55	Critical Values in the Coagulation Laboratory: Results of a Survey of the North American Specialized Coagulation Laboratory Association.. Blood, 2009, 114, 1415-1415.	0.6	1
56	Direct Thrombin Inhibitors. Fundamental and Clinical Cardiology, 2009, , 327-340.	0.0	0
57	Diagnostic Utility of Platelet Secretion Testing by ATP Release Assays: Results From a Prospective Study of Individuals Referred for Bleeding Disorder Assessments.. Blood, 2009, 114, 1314-1314.	0.6	2
58	An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thrombosis and Haemostasis, 2008, 100, 01-12.	1.8	20
59	Prospective Evaluation of An Argatroban Dosing Nomogram Using the Ecarin Chromogenic Assay at a Tertiary Institution. Blood, 2008, 112, 3016-3016.	0.6	0
60	An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thrombosis and Haemostasis, 2008, 100, 134-45.	1.8	55
61	Gender Differences in Bleeding Problems and Implications for the Assessment of a Bleeding Disorder.. Blood, 2007, 110, 2148-2148.	0.6	2
62	Stroke prevention in patients with atrial fibrillation: The diagnosis and management of hypertension by specialists. Canadian Journal of Cardiology, 2006, 22, 485-488.	0.8	9
63	Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review. Thrombosis Research, 2003, 111, 215-219.	0.8	65
64	Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood, 2001, 98, 257-265.	0.6	116